Qureight Raises $20M Series B for AI-Powered Lung and Heart Imaging
The Cambridge-based company will use its Series B funding to expand its AI imaging platform into new disease areas for clinical trials.
AfroEuropa Newsroom
AfroEuropa desk
Qureight, a Cambridge, UK-based company that develops AI imaging tools and precision endpoints for lung and heart disease clinical trials, has raised $20 million in a Series B financing round. The round was led by Molten Ventures, with returning investors Hargreave Hale AIM VCT, XTX Ventures, Guinness Ventures, Meltwind, and Ascension also participating. According to Tech.eu, the round brings the company's total funding to more than €27 million.
The company was co-founded in 2018 by Dr Muhunthan Thillai and Dr Alessandro Ruggiero. Thillai, a chest physician who still sees patients part-time in Cambridge, told Tech Funding News that the idea grew out of a case in which he could not confidently interpret a CT scan, pointing to an opportunity to help pharmaceutical companies run better clinical trials. To address the founders' lack of an engineering background, Qureight brought on a CTO who was previously global head of platform at Hewlett Packard, a CMO who led research at CMR Surgical, and a CSO who formerly taught machine learning at Imperial College London.
Keep reading
London's Ares Intelligence Raises €2.9M to Map Enterprise AI Adoption
The London startup, backed by Creandum and Lakestar, uses an AI interviewer to help organisations identify where to deploy AI.
Other highlights
Wall Street Analysts Suggest Buying Crypto Stocks After Binance Hack
Analysts at Cantor Fitzgerald, TD Cowen and Compass Point say a multibillion-dollar Binance breach is unlikely to stall the crypto market's recovery.
Follow the story
One newsletter, two continents
The Bridge brings you the tech, startups, and leaders moving between Africa and Europe in one sharp email each morning. No spam, unsubscribe anytime.
